Key result
Initiation of clopidogrel therapy and smoking cessation decreased coated-platelet levels at 90 days after ischemic stroke compared to baseline.
Why the study?
To investigate whether initiating treatment with SSRIs, statins, clopidogrel, aspirin, or oral anticoagulants, or smoking cessation, impacts coated-platelet levels at 90 days after ischemic stroke.
Does initiation of clopidogrel or smoking cessation reduce coated-platelet levels in patients with ischemic stroke?
Observational (n=87)
Does initiation of clopidogrel or smoking cessation reduce coated-platelet levels in patients with ischemic stroke?
Clopidogrel therapy and smoking cessation significantly attenuate procoagulant coated-platelet levels at 90 days following an ischemic stroke.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for post-stroke platelet modulation; randomized trials needed before changing practice.
Coated-platelets are a subset of highly procoagulant platelets elevated in patients with non-lacunar ischemic stroke and associated with stroke recurrence. Cross-sectional studies in controls have shown that smoking is associated with higher coated-platelet levels while chronic use of serotonin reuptake inhibitors (SSRIs), statins or aspirin is associated with lower coated-platelet levels. We now investigate if initiation of treatment with SSRIs, statins, clopidogrel, aspirin or oral anticoagulants and smoking cessation impacts coated-platelet levels at 90 days after ischemic stroke. Coated-platelet levels, reported as percent of cells converted to coated-platelets, were measured in 87 consecutive patients with stroke at baseline and repeated at 90 days. Repeated-measure ANOVA was used to determine if initiation of treatment with individual medications or smoking cessation impacted coated-platelet levels. Decreased coated-platelets levels at 90 days as compared to baseline were observed after initiation of treatment with clopidogrel (p = .0001, partial η2 = 0.17) and smoking cessation (p = .014, partial η2 = 0.10). Initiation of treatment with SSRIs, statins, aspirin or oral anticoagulants did not result in significant changes in coated-platelet potential. These novel longitudinal data suggest that clopidogrel therapy and smoking cessation attenuate coated-platelet potential at 90 days after ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Kirkpatrick et al. (2019) conducted an observational in Ischemic stroke (n=87). Clopidogrel therapy and smoking cessation vs. Baseline was evaluated on Coated-platelet levels (percent of cells converted to coated-platelets) at 90 days (partial η2 = 0.17 (clopidogrel); partial η2 = 0.10 (smoking cessation), p=0.0001 (clopidogrel); 0.014 (smoking cessation)). Initiation of clopidogrel therapy and smoking cessation decreased coated-platelet levels at 90 days after ischemic stroke compared to baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: